William Blair Has Positive Estimate for VRTX FY2025 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at William Blair increased their FY2025 earnings estimates for Vertex Pharmaceuticals in a research report issued on Thursday, December 19th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will post earnings of $16.65 per share for the year, up from their prior forecast of $16.61. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.83) per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the prior year, the company earned $3.67 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis.

Other analysts have also issued reports about the stock. Morgan Stanley increased their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Barclays lowered their price target on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a report on Friday. UBS Group increased their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $499.77.

Vertex Pharmaceuticals Stock Up 0.2 %

Shares of Vertex Pharmaceuticals stock opened at $397.27 on Monday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a 50-day moving average price of $470.41 and a 200 day moving average price of $475.30. The company has a market cap of $102.31 billion, a P/E ratio of -199.63 and a beta of 0.36.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several hedge funds have recently modified their holdings of VRTX. Edgewood Management LLC raised its stake in Vertex Pharmaceuticals by 7,876.3% during the 3rd quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock valued at $719,186,000 after purchasing an additional 1,526,983 shares during the last quarter. Jennison Associates LLC raised its position in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock valued at $2,581,373,000 after buying an additional 851,054 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Vertex Pharmaceuticals by 17.2% in the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after buying an additional 704,421 shares during the period. International Assets Investment Management LLC grew its position in Vertex Pharmaceuticals by 74,015.5% during the third quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company’s stock worth $150,977,000 after buying an additional 324,188 shares in the last quarter. Finally, AustralianSuper Pty Ltd bought a new position in Vertex Pharmaceuticals during the third quarter valued at about $105,282,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.